Author:
Peshkov Maksim N.,Sharova E. I,Klabukov I. D
Abstract
The last ten years have significantly changed the diagnostic and therapeutic technologies in research and practice. Human genome from a large international project turns into a basis of personalized medicine. The paper presents the positive experience of the new technology experimental thinking that led to the creation of complex scientific and technological platform that allows you to significantly improve the diagnostic characteristics (sensitivity, specificity) of the traditional PSA test. This paper presents the experimental results, which can improve the specificity and sensitivity of existing diagnostic methods.
Reference16 articles.
1. Чиссов В.И., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2010 г. (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздравсоцразвития России. 2012.
2. Jemal A., Bray F., Center M. M. et al. Global cancer statistics. CA. Cancer J. Clin. 2011; 61(2): 69-90.
3. Wang M.C., Valenzuela L.A., Murphy G.P, Chu T.M. Purification of a human prostate specific antigen. Invest. Urol. 1979; 17: 159-63.
4. Catalona W.J., Partin A.W., Slawin K.M., Brawer M., Flanigan R., Patel A. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J. A. M. A. 1998; 279 (19): 1542-7.
5. Catalona W.J., Smith D.S., Ratliff T.L., Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J. A. M. A. 1993; 270 (8): 948-54.